Anna Lluch - Grifols SA Independent Director
GRFS Stock | USD 6.39 0.09 1.39% |
Director
Ms. Anna Veiga Lluch serves as Independent Director of Grifols, S.A. since December 9, 2008. In the past, she acted as Director of the Reproductive Medicine Department of Instituto Universitario Dexeus, from 1982 to 2004, Coordinator of the Special Interest Group in Stem Cells of the European Society for Human Reproduction and Embryology, from 2005 to 2008 Scientific Coordinator of the European Project of European Human Ennyonic Stem Cell Registry, from 2002 to 2010 President of Association Espanola para el Estudio de la Biologia de la Reproduccion, from 1993 to 2003, Member of the Executive Committee of Alpha Scientists in Reproductive Medicine from 1998 to 2002, Member of the Consultants Committee for Bioethics at the Health Department of Cataluna, and Member of the Executive Committee of the European Society for Human Reproduction and Embryology, among others. Since 2005, she was Member of the Consultants Committee of the European Assisted Conception Consortium, and since 2008, she has served as Member of the International Committee of the International Society for Stem Cell Research . In addition, she is Member of the Patronage of Fundacion IrsiCaixa, Banc de Sang i Teixits and Circulo de Economica. She graduated in Biology and holds a Doctorate in Philosophy degree in Biology from Universitat Autonoma de Barcelona in 1991. since 2008.
Tenure | 16 years |
Address | Avinguda de la Generalitat, 152, Barcelona, Spain, 08174 |
Phone | 34 935 712 200 |
Web | https://www.grifols.com |
Grifols SA Management Efficiency
The company has return on total asset (ROA) of 0.0214 % which means that it generated a profit of $0.0214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.022 %, meaning that it created $0.022 on every $100 dollars invested by stockholders. Grifols SA's management efficiency ratios could be used to measure how well Grifols SA manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0 in 2024. Return On Capital Employed is likely to drop to 0.04 in 2024. At this time, Grifols SA's Asset Turnover is comparatively stable compared to the past year.Similar Executives
Showing other executives | DIRECTOR Age | ||
Roy Anderson | GlaxoSmithKline PLC ADR | 69 | |
Manuel Medina | Bristol Myers Squibb | 53 | |
Dimitri Azar | Novartis AG ADR | 59 | |
Phyllis Yale | Bristol Myers Squibb | 63 | |
Frank Herringer | Amgen Inc | 74 | |
Vicki Sato | Bristol Myers Squibb | 71 | |
DeAnne Julius | Roche Holding Ltd | 66 | |
Lynn Schenk | Biogen Inc | 73 | |
Hans Wijers | GlaxoSmithKline PLC ADR | 64 | |
Kevin Lofton | Gilead Sciences | 63 | |
Claudia Dyckerhoff | Roche Holding Ltd | 51 | |
John Madigan | Gilead Sciences | 77 | |
Michael Bonney | Bristol Myers Squibb | 61 | |
Tyler Jacks | Amgen Inc | 57 | |
Inge Thulin | Merck Company | 67 | |
Carla Hills | Gilead Sciences | 80 | |
Caroline Dorsa | Biogen Inc | 58 | |
Peter Voser | Roche Holding Ltd | 59 | |
Ellen Kullman | Amgen Inc | 62 | |
Bridgette Heller | Novartis AG ADR | 59 | |
Alexander Denner | Biogen Inc | 48 |
Management Performance
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 |
Grifols SA ADR Leadership Team
Elected by the shareholders, the Grifols SA's board of directors comprises two types of representatives: Grifols SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Grifols. The board's role is to monitor Grifols SA's management team and ensure that shareholders' interests are well served. Grifols SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Grifols SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Antonio Pares, Director of Planning and Control | ||
Alberto Roura, President Division | ||
Carsten Schroeder, President Of The Diagnostic Division | ||
Albert Roura, CEO of Laboratorios Grifols SA | ||
Lafmin Morgan, President Of The Bioscience And Hospital Division | ||
Juan Roura, Vice President of Production, Executive Director | ||
Eva Tubau, Chief Scientific Officer | ||
Anna Lluch, Independent Director | ||
Carlos Fernandez, Deputy Industrial Vice President | ||
Jose Gras, Director, Representative of Thorthol Holdings BV | ||
Maria Llano, Chief Officer | ||
Edgar Jannotta, Independent Director | ||
Vicente Torre, Chief Officer | ||
Nacho Abia, CEO Director | ||
Mateo Humbert, Director of Human Resources | ||
Montserrat Calvo, Chief Administrative Officer, Controller | ||
Montserrat Llamas, Chief Officer | ||
Ramon Roca, Vice-President of Marketing and Sales and Executive Director | ||
Vctor Deu, CoCEO Director | ||
David Bell, Vice President of Corporate Operations and Development of Grifols Inc and United States Subsidiaries | ||
Victor Deu, Co-CEO, Executive Director | ||
Luis Bobadilla, Independent Director | ||
Inigo Mardones, Director | ||
Thomas Glanzmann, Executive Chairman | ||
Carina Lazaro, Independent Director | ||
Joel Abelson, President of North America Commercial Division of Grifols Inc | ||
Steven Mayer, Director | ||
Javier Ribes, CEO of Instituto Grifols SA | ||
Alfredo Guerra, CFO and Corporate VP | ||
Raimon Roura, Non-Member Secretary of the Board | ||
Victor Roura, Chairman, CEO and President and Member of Appointments and Remuneration Committee | ||
Brett Ingersoll, Director | ||
Shinji Wada, President of Plasma Centers of Grifols Inc | ||
Tomas Gelabert, Director | ||
Nuria Lapea, Risk Treasury | ||
Sergio Adell, President Support | ||
M Tubau, Corporate Affairs | ||
Steven JD, Ex Chairman | ||
Marla Salmon, Independent Director | ||
Nuria Barnes, Non-Member Assistant Secretary of the Board | ||
Gregory Rich, President of Grifols Inc and Subsidiaries in the US | ||
Belen Morenes, Independent Director | ||
Nuria Lapena, Director of Shareholder and Investor Relations |
Grifols Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Grifols SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.022 | ||||
Return On Asset | 0.0214 | ||||
Profit Margin | 0.01 % | ||||
Operating Margin | 0.13 % | ||||
Current Valuation | 16.55 B | ||||
Shares Outstanding | 679.09 M | ||||
Shares Owned By Institutions | 49.96 % | ||||
Number Of Shares Shorted | 5.97 M | ||||
Price To Earning | 14.34 X | ||||
Price To Book | 0.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Grifols SA ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Grifols SA ADR information on this page should be used as a complementary analysis to other Grifols SA's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Complementary Tools for Grifols Stock analysis
When running Grifols SA's price analysis, check to measure Grifols SA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Grifols SA is operating at the current time. Most of Grifols SA's value examination focuses on studying past and present price action to predict the probability of Grifols SA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Grifols SA's price. Additionally, you may evaluate how the addition of Grifols SA to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Commodity Directory Find actively traded commodities issued by global exchanges |
Is Grifols SA's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Grifols SA. If investors know Grifols will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Grifols SA listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.787 | Earnings Share 0.1 | Revenue Per Share 4.849 | Quarterly Revenue Growth 0.033 | Return On Assets 0.0214 |
The market value of Grifols SA ADR is measured differently than its book value, which is the value of Grifols that is recorded on the company's balance sheet. Investors also form their own opinion of Grifols SA's value that differs from its market value or its book value, called intrinsic value, which is Grifols SA's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Grifols SA's market value can be influenced by many factors that don't directly affect Grifols SA's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Grifols SA's value and its price as these two are different measures arrived at by different means. Investors typically determine if Grifols SA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Grifols SA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.